SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Ziopharm Oncology Inc – ‘10-Q/A’ for 6/30/12 – ‘EX-101.CAL’

On:  Tuesday, 8/28/12, at 4:07pm ET   ·   For:  6/30/12   ·   Accession #:  1144204-12-48414   ·   File #:  1-33038

Previous ‘10-Q’:  ‘10-Q’ on 8/2/12 for 6/30/12   ·   Next:  ‘10-Q’ on 11/8/12 for 9/30/12   ·   Latest:  ‘10-Q’ on 11/14/23 for 9/30/23

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 8/28/12  Ziopharm Oncology Inc             10-Q/A      6/30/12   50:3.1M                                   Toppan Merrill/FA

Amendment to Quarterly Report   —   Form 10-Q   —   Sect. 13 / 15(d) – SEA’34
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-Q/A      Amendment to Quarterly Report                       HTML     29K 
 2: EX-31.1     Certification -- §302 - SOA'02                      HTML     20K 
 3: EX-31.2     Certification -- §302 - SOA'02                      HTML     20K 
 4: EX-32.1     Certification -- §906 - SOA'02                      HTML     18K 
32: R1          Document and Entity Information                     HTML     37K 
23: R2          Balance Sheets                                      HTML    112K 
30: R3          Balance Sheets (Parenthetical)                      HTML     39K 
34: R4          Statements Of Operations                            HTML     67K 
46: R5          Statement Of Stockholders' Equity                   HTML     66K 
24: R6          Statement Of Stockholders' Equity (Parenthetical)   HTML     18K 
29: R7          Statements of Cash Flows                            HTML    142K 
21: R8          Business                                            HTML     26K 
15: R9          Summary of Significant Accounting Policies          HTML     19K 
47: R10         Collaborations and Alliances                        HTML     21K 
36: R11         Fair Value Measurements                             HTML     38K 
35: R12         Net Loss per Share                                  HTML     23K 
40: R13         Related Party Transactions                          HTML     22K 
41: R14         Commitments and Contingencies                       HTML     53K 
39: R15         Warrants                                            HTML     52K 
42: R16         Common Stock                                        HTML     19K 
31: R17         Stock-Based Compensation                            HTML     48K 
33: R18         Fair Value Measurements (Tables)                    HTML     27K 
38: R19         Net Loss per Share (Tables)                         HTML     22K 
50: R20         Warrants (Tables)                                   HTML     42K 
44: R21         Stock-Based Compensation (Tables)                   HTML     52K 
26: R22         Business - Additional Information (Detail)          HTML     23K 
37: R23         Collaborations and Alliances - Additional           HTML     24K 
                Information (Detail)                                             
28: R24         Assets and Liabilities Measured at Fair Value on    HTML     26K 
                Recurring Basis (Detail)                                         
13: R25         Potential Dilutive Shares Excluded from             HTML     26K 
                Computation of Diluted Net Loss Per Share (Detail)               
45: R26         Related Party Transactions - Additional             HTML     28K 
                Information (Detail)                                             
48: R27         Commitments and Contingencies - Additional          HTML    121K 
                Information (Detail)                                             
18: R28         Number of Warrants Outstanding (Detail)             HTML     21K 
17: R29         Warrants - Additional Information (Detail)          HTML     74K 
19: R30         Assumptions Used In Binomial Valuation Model and    HTML     25K 
                Black-Scholes Valuation Model (Detail)                           
20: R31         Warrant Exercise (Detail)                           HTML     32K 
22: R32         Common Stock - Additional Information (Detail)      HTML     34K 
11: R33         Stock-Based Compensation Expense on All Employee    HTML     23K 
                and Non-Employee Awards (Detail)                                 
43: R34         Stock-Based Compensation - Additional Information   HTML     31K 
                (Detail)                                                         
25: R35         Fair Value of Stock Options Assumptions Using       HTML     34K 
                Black-Scholes Option Valuation Model (Detail)                    
27: R36         Stock Option Activity Under Stock Option Plan       HTML     83K 
                (Detail)                                                         
14: R37         Summary of Unvested Restricted Stock (Detail)       HTML     46K 
49: XML         IDEA XML File -- Filing Summary                      XML     74K 
16: EXCEL       IDEA Workbook of Financial Reports (.xls)            XLS    392K 
 5: EX-101.INS  XBRL Instance -- ziop-20120630                       XML    731K 
 7: EX-101.CAL  XBRL Calculations -- ziop-20120630_cal               XML    109K 
 8: EX-101.DEF  XBRL Definitions -- ziop-20120630_def                XML    650K 
 9: EX-101.LAB  XBRL Labels -- ziop-20120630_lab                     XML    966K 
10: EX-101.PRE  XBRL Presentations -- ziop-20120630_pre              XML    726K 
 6: EX-101.SCH  XBRL Schema -- ziop-20120630                         XSD    147K 
12: ZIP         XBRL Zipped Folder -- 0001144204-12-048414-xbrl      Zip    101K 


‘EX-101.CAL’   —   XBRL Calculations — ziop-20120630_cal


This Exhibit is an XBRL XML File.


                                                                                                                                                                                
<?xml version="1.0" encoding="windows-1252"?>
<!-- EDGAR Online I-Metrix Xcelerate Taxonomy Calculation Linkbase, based on XBRL 2.1 http://www.edgar-online.com/ -->
<!-- Version: 6.17.6 -->
<!-- Round: 3 -->
<!-- Creation date: 2012-08-22T19:57:32Z -->
<!-- Copyright (c) 2005-2011 EDGAR Online, Inc. All Rights Reserved. -->
<linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DocumentDocumentandEntityInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DocumentDocumentandEntityInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_StatementOfFinancialPositionClassified" roleURI="http://www.ziopharm.com/taxonomy/role/StatementOfFinancialPositionClassified"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_StatementOfFinancialPositionClassifiedParen" roleURI="http://www.ziopharm.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_StatementOfIncomeAlternative" roleURI="http://www.ziopharm.com/taxonomy/role/StatementOfIncomeAlternative"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncome" roleURI="http://www.ziopharm.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_ci-StatementOfShareholdersEquityAndOtherComprehensiveIncomeParen" roleURI="http://www.ziopharm.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_StatementOfCashFlowsIndirect" roleURI="http://www.ziopharm.com/taxonomy/role/StatementOfCashFlowsIndirect"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureBusinessAdditionalInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureBusinessAdditionalInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureCollaborationsAndAlliancesAdditionalInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureCollaborationsAndAlliancesAdditionalInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosurePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShare" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosurePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShare"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureRelatedPartyTransactionsAdditionalInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureCommitmentsAndContingenciesAdditionalInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureNumberOfWarrantsOutstanding" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureNumberOfWarrantsOutstanding"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureWarrantsAdditionalInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureAssumptionsUsedInBinomialValuationModelAndBlackScholesValuationModel" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureAssumptionsUsedInBinomialValuationModelAndBlackScholesValuationModel"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureWarrantExercise" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureWarrantExercise"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureCommonStockAdditionalInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureStockBasedCompensationExpenseOnAllEmployeeAndNonEmployeeAwards" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureStockBasedCompensationExpenseOnAllEmployeeAndNonEmployeeAwards"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureStockBasedCompensationAdditionalInformation" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureFairValueOfStockOptionsAssumptionsUsingBlackScholesOptionValuationModel" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureFairValueOfStockOptionsAssumptionsUsingBlackScholesOptionValuationModel"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureStockOptionActivityUnderStockOptionPlan" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureStockOptionActivityUnderStockOptionPlan"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#DisclosureSummaryOfUnvestedRestrictedStock" roleURI="http://www.ziopharm.com/taxonomy/role/DisclosureSummaryOfUnvestedRestrictedStock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsFairValueDisclosuresTextBlockTables" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsEarningsPerShareTextBlockTables" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsCommonStockDisclosureTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
<roleRef xlink:type="simple" xlink:href="ziop-20120630.xsd#Role_NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables" roleURI="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"/>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DocumentDocumentandEntityInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/StatementOfFinancialPositionClassified">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AccruedLiabilitiesCurrent" xlink:label="us-gaap_AccruedLiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditCurrent" xlink:label="us-gaap_DeferredRentCreditCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRentCreditNoncurrent" xlink:label="us-gaap_DeferredRentCreditNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueCurrent" xlink:label="us-gaap_DeferredRevenueCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DeferredRevenueNoncurrent" xlink:label="us-gaap_DeferredRevenueNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepositsAssetsNoncurrent" xlink:label="us-gaap_DepositsAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" xlink:label="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAdditionalCapital" xlink:label="us-gaap_OtherAdditionalCapital"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ReceivablesNetCurrent" xlink:label="us-gaap_ReceivablesNetCurrent"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" order="1.0400" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" order="1.0500" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_DepositsAssetsNoncurrent" order="1.0600" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" order="1.0700" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" order="1.0100" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_ReceivablesNetCurrent" order="1.0200" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" order="1.0300" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" order="1.1200" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRevenueNoncurrent" order="1.1300" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredRentCreditNoncurrent" order="1.1400" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OtherLiabilitiesNoncurrent" order="1.1500" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" order="1.1600" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" order="1.2200" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" order="1.0800" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccruedLiabilitiesCurrent" order="1.0900" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRevenueCurrent" order="1.1000" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_DeferredRentCreditCurrent" order="1.1100" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_PreferredStockValue" order="1.1700" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" order="1.1800" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" order="1.1900" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_OtherAdditionalCapital" order="1.2000" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_DevelopmentStageEnterpriseDeficitAccumulatedDuringDevelopmentStage" order="1.2100" weight="-1.00" priority="2" use="optional"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/StatementOfFinancialPositionClassifiedParenthetical"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/StatementOfIncomeAlternative">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ContractsRevenue" xlink:label="us-gaap_ContractsRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingCostsAndExpenses" xlink:label="us-gaap_OperatingCostsAndExpenses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingGainsLosses" xlink:label="us-gaap_OtherNonoperatingGainsLosses"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss" order="1.0500" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingIncomeExpense" order="1.0600" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_OtherNonoperatingGainsLosses" order="1.0700" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_ResearchAndDevelopmentExpense" order="1.0200" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingCostsAndExpenses" xlink:to="us-gaap_GeneralAndAdministrativeExpense" order="1.0300" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ContractsRevenue" order="1.0100" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingCostsAndExpenses" order="1.0400" weight="-1.00" priority="2" use="optional"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncome"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/StatementOfShareholdersEquityAndOtherComprehensiveIncomeParenthetical"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/StatementOfCashFlowsIndirect">
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:label="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_DepreciationAndAmortization" xlink:label="us-gaap_DepreciationAndAmortization"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDeferredRevenue" xlink:label="us-gaap_IncreaseDecreaseInDeferredRevenue"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInDepositOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInDepositOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherDeferredLiability" xlink:label="us-gaap_IncreaseDecreaseInOtherDeferredLiability"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IncreaseDecreaseInReceivables" xlink:label="us-gaap_IncreaseDecreaseInReceivables"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" xlink:label="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_OtherNoncashIncomeExpense" xlink:label="us-gaap_OtherNoncashIncomeExpense"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:label="us-gaap_PaymentsForRepurchaseOfCommonStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromContributedCapital" xlink:label="us-gaap_ProceedsFromContributedCapital"/>
<loc xlink:type="locator" xlink:href="ziop-20120630.xsd#ziop_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" xlink:label="ziop_ProceedsFromIssuanceOfCommonStockAndWarrantsNet"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises"/>
<loc xlink:type="locator" xlink:href="http://xbrl.fasb.org/us-gaap/2012/elts/us-gaap-2012-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" order="1.1500" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" order="1.1800" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashAndCashEquivalentsPeriodIncreaseDecrease" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" order="1.2500" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromContributedCapital" order="1.1900" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromStockOptionsExercised" order="1.2000" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsForRepurchaseOfCommonStock" order="1.2100" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromWarrantExercises" order="1.2200" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="ziop_ProceedsFromIssuanceOfCommonStockAndWarrantsNet" order="1.2300" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" order="1.2400" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" order="1.1600" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" order="1.1700" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" order="1.0100" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationAndAmortization" order="1.0200" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" order="1.0300" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_OtherNoncashIncomeExpense" order="1.0400" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" order="1.0500" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IssuanceOfStockAndWarrantsForServicesOrClaims" order="1.0600" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInReceivables" order="1.0700" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" order="1.0800" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentAssets" order="1.0900" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDepositOtherAssets" order="1.1000" weight="-1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable" order="1.1100" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccruedLiabilities" order="1.1200" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInDeferredRevenue" order="1.1300" weight="1.00" priority="2" use="optional"/>
<calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInOtherDeferredLiability" order="1.1400" weight="1.00" priority="2" use="optional"/>
</calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureBusinessAdditionalInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureCollaborationsAndAlliancesAdditionalInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureAssetsAndLiabilitiesMeasuredAtFairValueOnRecurringBasis"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosurePotentialDilutiveSharesExcludedFromComputationOfDilutedNetLossPerShare"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureNumberOfWarrantsOutstanding"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureWarrantsAdditionalInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureAssumptionsUsedInBinomialValuationModelAndBlackScholesValuationModel"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureWarrantExercise"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureCommonStockAdditionalInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureStockBasedCompensationExpenseOnAllEmployeeAndNonEmployeeAwards"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformation"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureFairValueOfStockOptionsAssumptionsUsingBlackScholesOptionValuationModel"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureStockOptionActivityUnderStockOptionPlan"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/DisclosureSummaryOfUnvestedRestrictedStock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsBusinessDescriptionAndBasisOfPresentationTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsSignificantAccountingPoliciesTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsCollaborativeArrangementDisclosureTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsFairValueDisclosuresTextBlockTables"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsEarningsPerShareTextBlockTables"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsRelatedPartyTransactionsDisclosureTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsCommitmentsAndContingenciesDisclosureTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsStockholdersEquityNoteDisclosureTextBlockTables"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsCommonStockDisclosureTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"> </calculationLink>
<calculationLink xlink:type="extended" xlink:role="http://www.ziopharm.com/taxonomy/role/NotesToFinancialStatementsDisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlockTables"> </calculationLink>
</linkbase>

Top
Filing Submission 0001144204-12-048414   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Fri., Apr. 26, 2:13:02.1pm ET